No Data
12 Health Care Stocks Moving In Friday's Pre-Market Session
TD Cowen Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $10
BTIG Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $10
H.C. Wainwright Maintains Humacyte(HUMA.US) With Buy Rating, Raises Target Price to $15
Aptose APTO NASDAQ Compliance; Humacyte HUMA Full Approval
Humacyte's Symvess Gains FDA Approval and Positions for Market Success